Samis Jill, Lee Paul, Zimmerman Donald, Arceci Robert J, Suttorp Meinolf, Hijiya Nobuko
Division of Pediatric Endocrinology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Pediatr Blood Cancer. 2016 Aug;63(8):1332-8. doi: 10.1002/pbc.26028. Epub 2016 Apr 21.
Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to "off-target" effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.
酪氨酸激酶抑制剂（TKI）治疗慢性粒细胞白血病（CML）的副作用在儿童和成人中有所不同。由于儿童的预期寿命比成人长得多，TKI治疗可能会持续数十年，且产生的长期后果与成人不同。儿童可能会出现与TKI“脱靶”效应相关的内分泌疾病，如生长发育迟缓、骨代谢变化、甲状腺异常以及对青春期和生育能力的影响。这些内分泌疾病给患有CML的儿科患者带来了额外的挑战。本综述批判性地评估了有关TKI在儿童CML患者中长期内分泌副作用的文献，并提供了建议。
